Teva's 3rd interim analysis of pearl real-world study on ajovy® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. today announces further positive data from the pan-european pearl study investigating the impact of ajovy® (fremanezumab) on the prevention of migraine in a real-world setting,1 due to be completed in 2024. the data from the 3rd interim analysis2 reveals that almost 60% of patients achieved a ≥50% reduction in monthly migraine days from baseline for migraine prevention, with sustained improvement in disability scores and acu.
TEVA Ratings Summary
TEVA Quant Ranking